Drug name - Zeposia
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8796318 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
| US8481573 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
| CN102118972A | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| CN102118972B | CELGENE INTL | Regulator Of Sphingosine Phosphate Receptor |
May, 2029
(6 years from now) | |
| IN305486B | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| IN201818041445A | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| IN396031B | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| EP2913326B1 | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| EP2913326A1 | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| EP2291080A4 | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| EP2291080A1 | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| EP2291080B1 | CELGENE INTL | Novel Modulators Of Sphingosine Phosphate Receptors |
May, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9382217 | CELGENE INTL | Modulators of sphingosine phosphate receptors |
May, 2029
(6 years from now) | |
| US10239846 | CELGENE INTL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(8 years from now) | |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the treatment of moderately to severely active ulcerative colitis
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.23MG BASE | CAPSULE;ORAL | Prescription |
| EQ 0.46MG BASE | CAPSULE;ORAL | Prescription |
| EQ 0.92MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.